7 Houston-area hospitals receive first doses of COVID-19 vaccine

CORONAVIRUS NEWS

Front-line and health care workers will get the vaccine first. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Four sites in Texas received the COVID-19 vaccine on December 14, part of a rollout of doses being shipped out across the U.S.

Texas received 19,500 doses, with another 250,000 doses being distributed to 109 facilities in Texas this week.

According to the Texas Department of State Health Services, the first four sites to get it were:

  • MD Anderson Cancer Center in Houston
  • Methodist Dallas Medical Center
  • Wellness 360 at UT Health San Antonio
  • UT Health Austin's Dell Medical School

Another 75,000 doses will be delivered on December 15 to 19 sites in Texas:

  • Houston, Texas Children's Hospital Main
  • Houston, LBJ Hospital
  • Houston, CHI St. Luke's Health
  • Houston, Memorial Hermann Texas Medical Center
  • Houston, Houston Methodist Hospital
  • Houston, Ben Taub General Hospital
  • Galveston, University of Texas Medical Branch Hospital
  • Amarillo, Texas Tech Univ. Health Science Center Amarillo
  • Corpus Christi, Christus Spohn Health System Shoreline
  • Dallas, Parkland Hospital
  • Dallas, UT Southwestern
  • Edinburg, Doctors Hospital at Renaissance
  • Edinburg, UT Health RGV Edinburg
  • El Paso, University Medical Center El Paso
  • Fort Worth, Texas Health Resources Medical Support
  • Lubbock, Covenant Medical Center
  • San Angelo, Shannon Pharmacy
  • Temple, Baylor Scott and White Medical Center

Health care and front-line workers will receive the vaccine first. Officials are still working out the timeline but the general public is not expected to get the vaccine until spring 2021 at the earliest.

Dr. Paul Klotman, president of the Baylor College of Medicine in Houston, said in a press conference that getting vaccinated is helpful to both individuals and their communities.

"The thing about everyone pitching in, do it for yourself because it will help protect you, but when you get the herd immunity it will help protect people who are unable medically to get the vaccine," Klotman said.

------

This article originally ran on CultureMap.

This week's Houston innovators to know includes Sola Lawal of Nuro, Jose Diaz-Gomez of CHI St. Luke's Health, and Kimberly Baker of UT School of Public Health. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: A key attribute of innovators and inventors is the ability to look forward — to see the need for their innovation and the difference it will make. Each of this week's innovators to know have that skill, whether it's predicting the rise of autonomous vehicles or seeing the future of health care.

Sola Lawal, product operations manager at Nuro

Autonomous vehicle delivery service is driving access to food in Houston’s vulnerable communities

Native Houstonian Sola Lawal is looking into how AI and robotics can help increase access to fresh foods in local food deserts. Photo courtesy of Nuro

Sola Lawal has always found himself back in his hometown of Houston. Now working for artificial intelligence and robotics company, Nuro, he sees the potential Houston has to become a major market for autonomous vehicles.

"I think that autonomous vehicles are going to become an industry in the same way your standard vehicles are," Lawal says."One really strong way the Houston ecosystem and Nuro can partner is essentially building out the ancillary."

Lawal shared more on how Houston and Nuro can work together on this week's episode of the Houston innovators podcast. Read more and stream the episode.

Jose Diaz-Gomez, an anesthesiologist at CHI St. Luke's Health

CHI St. Luke's Health has invested in around 40 of the Butterfly iQ devices that can be used to provide accurate and portable ultrasonography on COVID-19 patients. Photo courtesy of CHI St. Luke's

A new, portable ultrasound device has equipped Jose Diaz-Gomez and his team with a reliable, easy-to-use tool for diagnostics and tracking progress of COVID-19 patients. And this tool will continue to help Diaz-Gomez lead his team of physicians.

"Whatever we will face after the pandemic, many physicians will be able to predict more objectively when a patient is deteriorating from acute respiratory failure," he says. "Without this innovation, we wouldn't have been able to be at higher standards with ultrasonography." Read more.

Kimberly A. Baker, assistant professor at UTHealth School of Public Health

UTHealth School of Public Health launched its Own Every Piece campaign to promote women's health access and education. Photo courtesy of Own Every Piece

It was unnerving to Kimberly Baker that proper sex education wasn't in the curriculum of Texas schools, and women were left without resources for contraceptives. So, along with UTHealth School of Public Health, she launched its Own Every Piece campaign as a way to empower women with information on birth control and ensure access to contraceptive care regardless of age, race, relationship status or socioeconomic status.

"You feel like the campaign is talking to you as a friend, not talking down to you as an authority or in any type of shaming way," says Kimberly A. Baker, assistant professor at UTHealth School of Public Health. One of her favorite areas of the website is the "Find a Clinic" page, connecting teens and adult women to nearby clinics, because "one of the biggest complaints from women is that they didn't know where to go," says Baker. Continue reading.

CHI St. Luke's Health has invested in around 40 of the Butterfly iQ devices that can be used to provide accurate and portable ultrasonography on COVID-19 patients. Photo courtesy of CHI St. Luke's

Houston hospital taps new tech to provide more accurate COVID-19 diagnostics and treatment

hand held

With such a dynamic virus like COVID-19 that affects patients with different levels of severity, the first challenge doctors face when treating infected patients is assessing the situation. CHI St. Luke's Health has been implementing a new technology that allows its physicians better access to that initial diagnosis.

Dr. Jose Diaz-Gomez, an anesthesiologist at CHI St. Luke's Health and ultrasonography expert, says the Butterfly iQ's portable ultrasonography technology has been a key tool in his team's point of care for COVID-19 patients. Over the past few years, ultrasonography equipment has been evolving to be more portable and more accurate. That's what the Butterfly iQ technology provides, and Diaz-Gomez says his team was quick to realize how the technology can help in diagnostics and treatment of coronavirus patients.

A traditional approach to examining a patient's lungs would mean radiography, but Diaz-Gomez says his team saw the opportunity ultrasonography and these new, portable devices had on providing more accurate and timely diagnostics.

"In conditions that are dynamic, you want to have a diagnostic tool that, over time as you're treating a patient, you can see meaningful changes — good or bad," Diaz-Gomez says. "The pandemic has enabled us to use — from the initial care to when they are on the ventilator — ultrasonography to see the changes in the patient's' lungs."

Jose Diaz-Gomez is an anesthesiologist at CHI St. Luke's. Photo courtesy of CHI St. Luke's

The Butterfly iQ device is different from its ultrasound predecessors in that it's built to be more accurate, portable, easy to use, and low cost (even being made available for commercial purchase). According to Diaz-Gomez, he could train someone on the device in just a few hours.

Ahead of the pandemic, CHI St. Luke's had 20 of these devices and now has doubled that initial fleet. Along with the other non-Butterfly iQ ultrasonography devices, Diaz-Gomez's team has access to 70 ultrasonography devices — 80 percent of which are dedicated to COVID-19 patients.

"Our institution was very supportive of bringing a very robust roll-out program for point-of-care ultrasonography during the pandemic," Diaz-Gomez says. "We were able to incorporate 40 ultrasound devices — the Butterfly system. Not only that, we actually implemented a very rigorous infection control process to make sure we do it in a safe manner. You don't want to bring tools that will be another source of transmission from patient to patient."

While this new technology is continuing to make a difference in St. Luke's COVID units, Diaz-Gomez is already looking forward to the difference the devices will make post pandemic.

"Whatever we will face after the pandemic, many physicians will be able to predict more objectively when a patient is deteriorating from acute respiratory failure," he says. "Without this innovation, we wouldn't have been able to be at higher standards with ultrasonography."

The device, with its portability, low cost, and ease of use, also has an application for telemedicine and at-home health, and that's something that's exciting for Diaz-Gomez. However, both in his COVID units or in the home setting, the device is only as good as the clinician who's interpreting the images paired with the other diagnostics.

"The integration of ultrasonography with the clinical practice itself — it has to go hand in hand," Diaz-Gomez says. "The clinical decision will depend on that integration."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

SpaceX IPO set to be biggest ever and could make Elon Musk a trillionaire

IPO News

SpaceX says it plans to raise up to $75 billion when it goes public this month, setting the stage for the largest-ever stock market debut and putting Elon Musk on course to becoming the world's first trillionaire.

The company, formally known as Space Exploration Technologies Corp., said Wednesday it will sell 555.6 million shares at $135 a piece in an initial public offering. The estimated proceeds would easily top the $26 billion raised by oil giant Saudi Aramco in 2019. The offering would also give SpaceX a market value of $1.77 trillion. Only six companies in the S&P 500 are currently worth more, with Nvidia tops at $5.2 trillion.

Besides the size of the offering and the expected proceeds, SpaceX's amended prospectus updates details about how much control of the company Musk will have. As SpaceX's CEO, chief technical officer and chairman, Musk's voting power will come primarily through his ownership of 5.22 billion Class B shares, which give the holder 10 votes for every share held. According to the filing, Musk would have 82.4% of the voting power in the company.

Forbes currently values Musk's net worth at $826 billion and his stake in SpaceX at $542 billion. The estimated value of his SpaceX holdings was based on an overall value for the company of $1.25 trillion. Based on those numbers, a $1.77 trillion valuation for SpaceX would boost Musk's net worth by $223 billion, making him a trillionaire. However, much of Musk's worth is in stock that he has yet to cash in.

Even as it makes a bid for a blockbuster market debut, SpaceX is currently losing billions of dollars a year. The filing shows that the company lost $2.6 billion from operations last year on $18.7 billion in revenue, and the losses kept piling up at the start of this year, too.

Fantastical plans

Time will tell how SpaceX fares on the market. Musk's plans for the company are as fantastical as the money he hopes raise in the sale.

Colorful, even frightening in parts, the IPO document strikes a contrast with the typically dry, technical prose in IPO documents, detailing plans to use proceeds from the sale to help put men on the moon again and perhaps even Mars. In one section, it talks of a need to build "a permanent human colony" on the red planet with "at least one million inhabitants" as existential threats loom that could consign man to "the same fate as the dinosaurs."

Musk has almost equally ambitious plans for his other publicly traded company, Tesla. His goal is to transform the maker of electric vehicles into a producer of robotaxis and humanoid robots. Dan Ives of Wedbush Securities wrote in a research note that he expects Tesla and SpaceX to merge next year.

AI plays a key role

Key to the success of both companies — and any merged entity — is artificial intelligence. In its IPO filing, SpaceX says it sees potential revenue from AI of up to $26.5 trillion. But that depends on another lofty Musk ambition — putting data centers in space, which is not technologically possible at the moment.

Transforming his space company into a primarily AI-focused company will be a challenge for Musk, who started xAI in 2023 with 11 other co-founders who have all since left. Some were recruited away by rivals.

Its main AI product, the chatbot Grok, is "less impressive than anything that we see from any other major player in the space, whether that's OpenAI, or Anthropic, or (Google's) Gemini," said IDC analyst Arnal Dayaratna.

Dayaratna said that doesn't mean SpaceX doesn't have potential as a major AI player, thanks in part to its computing partnership with Anthropic and Musk's recent deal that gave SpaceX the rights to buy AI coding tool Cursor for $60 billion later this year. Folding in Cursor's capabilities would give SpaceX access to the coveted business customers now using Anthropic's Claude or OpenAI's ChatGPT.

SpaceX plans to use the net proceeds from the IPO to fund the expansion of infrastructure for its AI and rocket businesses, and to beef up the constellation of satellites that power Starlink Mobile, among other investments.

The company plans to list on the Nasdaq under the symbol "SPCX" and could begin trading as soon as the end of next week.

And SpaceX isn't the only colossal market debut investors are now bracing for. Earlier this week, Anthropic submitted a confidential filing with the U.S. Securities and Exchange Commission to officially start its own IPO clock.

OpenAI has not yet reported filing the initial SEC paperwork, but an IPO from the ChatGPT maker is widely expected.

"This listing represents the first major test for public markets after years of muted IPO activity with SpaceX paving the way for AI giants Anthropic and OpenAI to follow soon after," Ives wrote.

___

Associated Press Technology Writer Matt O'Brien contributed.

New UH survey reveals concerns over AI data center growth in Houston

data findings

A new report out of the University of Houston shows that area residents remain wary of the long-term effects of operating data centers.

The recent survey from the University of Houston’s latest SPACE City Panel, conducted by the Center for Public Policy at the Hobby School of Public Affairs, shows that while 85 percent of Houston-area residents use AI, nearly 63 percent oppose the construction of AI data centers within 1 mile of their homes.

Respondents’ concerns centered around data centers’ high energy demand and the area’s power grid reliability. According to the survey, 32 percent of residents who oppose local data center projects would be more likely to support the centers if they relied on renewable energy over fossil fuels.

“Respondents understand that AI can bring economic and educational benefits, but they are also concerned about the physical infrastructure needed to fuel AI, especially data centers,” Soran Mohtadi, post-doctoral fellow at the Hobby School and a researcher on the report, said in a news release. “This physical infrastructure demands more electricity and water, leading to environmental impacts.”

Experts estimate that 6.5 gigawatts of data center capacity will be added to the Texas grid by 2030. And Houston’s data center capacity is predicted to more than double by 2028.

The Electric Reliability Council of Texas also projects electricity demand could reach 218 gigawatts by 2031, which would be more than double the record peak set in August 2023. Data centers are expected to account for 86 gigawatts of that new demand.

Survey respondents also said they are concerned about the state's future water supply, given the large amounts of water that data centers need to stay cool.

In terms of who’s responsible for that issue, 57.6 percent of respondents said they put the onus on Texas lawmakers, while 31.5 percent say tech companies should be responsible.

Additionally, more than 75 percent of respondents believed that data center developers and technology companies—not residents—should bear the cost of infrastructure upgrades to support data centers.

“Every decision legislators make has implications on residents’ everyday lives and local infrastructure now and in the future,” Maria P. Perez Arguelles, lead researcher on the report and research assistant professor at the Hobby School, added in the news release. “This issue is going to become more important in years to come, so this is just the beginning.”

Read the full report here.

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

View All Listings